ABSTRACT

In this investigation, a murine model of tumorigenesis and programmed cell death was employed to assess the impact of Tacrolimus and Doxorubicin. A total of forty female BALB/c mice were assigned randomly to one of four experimental groups: control (Group 1), Doxorubicin (Dox) treatment (Group 2), pre-tumor induction (Group 3), and post-tumor induction Tacrolimus treatment (Group 4). Tumours were induced using murine cancer cell lines, followed by the administration of therapeutic interventions. The flow cytometric analysis, employing Annexin V/PI labelling, revealed statistically significant differences in the proportions of live, early apoptotic, late apoptotic, and dead cells among the various experimental groups. The administration of tacrolimus therapy, particularly when administered before to the development of tumours, induced a significant level of apoptosis. Conversely, the administration of doxorubicin led to a substantial rise in the number of apoptotic cells in the animals that received the treatment. The findings were supported by a histological examination of cancer tissue, which demonstrated notable changes in cellular quantity, nuclear condensation, and cellular membrane integrity within the experimental groups. In summary, our study employs a mouse cancer model to demonstrate that Tacrolimus effectively triggers apoptosis, whereas Doxorubicin, a widely recognized cytotoxic drug, effectively hinders tumour growth. The findings of this study indicate encouraging therapeutic outcomes associated with these interventions, hence emphasizing the need for further exploration into strategies for optimizing treatment protocols to enhance the efficacy of cancer therapy.